Join
Live feed
·
PRReleasevia Quantisnow
bluebird bio Inc. logo

bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

ByQuantisnow·Wall Street's wire, on your screen.
BLUE· bluebird bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BLUE (bluebird bio Inc.) and more on Quantisnow.